These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24169086)

  • 21. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
    Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
    Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
    Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
    Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
    Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
    Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
    Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
    [No Abstract]   [Full Text] [Related]  

  • 28. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
    He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
    Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Detection of chromosomal aberrations in multiple myeloma with fluorescence in situ hybridization].
    Cao P; Chen F; Cheng Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 37(10):983-9. PubMed ID: 23117450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study on molecular cytogenetic abnormalities in multiple myeloma].
    Liu SY; Li JY; Chen LJ; Huang JW; Pan JL; Qiu HR; Shen YF; Xu W; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Apr; 28(4):223-6. PubMed ID: 17877196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosome 1 abnormalities in multiple myeloma.
    Marzin Y; Jamet D; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
    Anticancer Res; 2006; 26(2A):953-9. PubMed ID: 16619492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular cytogenetic aberrations in Tunisian patients with multiple myeloma identified by cIg-FISH in fixed bone marrow cells.
    Gmidène A; Avet-Loiseau H; Sennana H; Ben Abdallah I; Khlif A; Meddeb B; Elloumi M; Saad A
    Cytogenet Genome Res; 2012; 136(1):44-9. PubMed ID: 22188899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
    Chang H; Yeung J; Xu W; Ning Y; Patterson B
    Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Frequency and prognostic value of chromosome abnormalities in multiple myeloma].
    Kurahashi S; Sawamoto A; Sugimoto T; Narimatsu H; Iwasaki T; Adachi T; Suzuki H; Hayakawa F; Sugiura I
    Rinsho Ketsueki; 2007 Nov; 48(11):1455-61. PubMed ID: 18080502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.
    Schmidt-Wolf IG; Glasmacher A; Hahn-Ast C; Jüttner A; Schnurr T; Cremer F; Moehler T; Goldschmidt H; Busert B; Schubert R; Schwanitz G
    Cancer Genet Cytogenet; 2006 May; 167(1):20-5. PubMed ID: 16682281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
    Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
    Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.